[
  {
    "ts": null,
    "headline": "Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock",
    "summary": "Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and “triple pill” regimens. The company’s pipeline can potentially exceed expectations if the data is positive. The analyst views the risk/reward balance as mostly neutral for 2024. The pain program stands out as a potential blockbuster, especially with the upcoming launch for acute pai",
    "url": "https://finnhub.io/api/news?id=1c4961c2b67738438a418ac660faec87d7887b85429b58c27839092a7de732ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733768616,
      "headline": "Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock",
      "id": 131901259,
      "image": "",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and “triple pill” regimens. The company’s pipeline can potentially exceed expectations if the data is positive. The analyst views the risk/reward balance as mostly neutral for 2024. The pain program stands out as a potential blockbuster, especially with the upcoming launch for acute pai",
      "url": "https://finnhub.io/api/news?id=1c4961c2b67738438a418ac660faec87d7887b85429b58c27839092a7de732ad"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=c734adbb0424965f3cb1a57c517e64dfd5a7ce4c2cce612f7c6eb90607f3e266",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733762460,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 131936106,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=c734adbb0424965f3cb1a57c517e64dfd5a7ce4c2cce612f7c6eb90607f3e266"
    }
  },
  {
    "ts": null,
    "headline": "2 No-Brainer Stocks to Buy Before the End of 2024",
    "summary": "The legendary investor continues to be a net seller of stocks, and has amassed a record-high cash stockpile for Berkshire Hathaway.  As I wrote recently, Buffett is being fearful while others are greedy.  Let's first get the bad news for BioNTech (NASDAQ: BNTX) out of the way.",
    "url": "https://finnhub.io/api/news?id=b0fc54b06f4bb082e5e7926f7ec94642cb3e6fbccc7677a17463b0457d08fd1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733741400,
      "headline": "2 No-Brainer Stocks to Buy Before the End of 2024",
      "id": 131868087,
      "image": "https://g.foolcdn.com/editorial/images/800169/hands-behind-head-young-man.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The legendary investor continues to be a net seller of stocks, and has amassed a record-high cash stockpile for Berkshire Hathaway.  As I wrote recently, Buffett is being fearful while others are greedy.  Let's first get the bad news for BioNTech (NASDAQ: BNTX) out of the way.",
      "url": "https://finnhub.io/api/news?id=b0fc54b06f4bb082e5e7926f7ec94642cb3e6fbccc7677a17463b0457d08fd1e"
    }
  },
  {
    "ts": null,
    "headline": "Gene therapy uptake in sickle cell stays slow, despite patient interest",
    "summary": "A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of Casgevy and Lyfgenia during their first year on market.",
    "url": "https://finnhub.io/api/news?id=0ce80b990f3700134977ba9ec5997b94cdcdf6ebcc47b368efb52fbb2493a89e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733734800,
      "headline": "Gene therapy uptake in sickle cell stays slow, despite patient interest",
      "id": 131869535,
      "image": "https://imgproxy.divecdn.com/CXyh-5cBM5loH5fiT5gN3d1cCI-QCOdH7bGEpHRbC7Q/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTcwOTEzMjEwLmpwZw==.webp",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of Casgevy and Lyfgenia during their first year on market.",
      "url": "https://finnhub.io/api/news?id=0ce80b990f3700134977ba9ec5997b94cdcdf6ebcc47b368efb52fbb2493a89e"
    }
  }
]